To accelerate the translation of basic research on molecular and cellular repair of age-related damage into actual human therapies we support the creation of startups in this field.
The teams develop therapies in the areas of senolytics, lysosomal clearance, induced tissue regeneration, stemcell restoration, young plasma factors, AGE breakers, novel cancer therapies, and aging biomarkers.
Mentoring and support for these teams are handled by Michael Greve's VC company Kizoo.
Revel opens up an entirely new field in the treatment of age-related molecular damage - breaking crosslinked collagen fibers.
Collagen is an essential part of the structural framework of the body. Unfortunately, it sometimes binds with glucose to form stiff, sofar unbreakable bonds that accumulate over time. Crosslinks cause hardening of tissues such as muscle, skin, and arteries leading to increased blood pressure, vascular damage, and wrinkling of the skin.
Based on 10 years of research by Yale Professors David Spiegel and Jason Crawford Revel will produce crosslink-breaking drugs.
Underdog develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.
Its products are based on novel derivatives of a well-known, safe compound, and a new way of looking at cardiovascular disease created through a SENS Research Foundation program.
LIfT Biosciences is developing the world's first cell therapy to destroy all solid tumours, irrespective of strain or mutation by building the World's 1st cell bank of innately cancer killing neutrophils (a type of white blood cell).
The cell bank will enable LIfT to provide a range of potentially life-saving immuno-oncology cell therapies for different solid tumour types. The first step is to show remission in high unmet need solid tumours by 2021, including Pancreatic Cancer.
MAIA Biotechnology is dedicated to developing targeted cancer therapies with novel mechanisms of action that are intended to meaningfully improve and extend the lives of patients with cancer.
Telomerase is present in 90% of human cancer cells and contributes significantly to proliferative abilities and immortality of cancer cells. It is either absent or shows low activity in normal cells. THIO(6-thio-dG) is recognized by telomerase and incorporated into telomeres. Once incorporated, it compromises telomere structure and function, leading to ‘uncapping’ of the chromosome ends resulting in rapid tumor cell death.
Turn Biotechnologies is developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered.
Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation of cellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells.
Elevian is a Harvard spinout developing therapeutics to stimulate regenerative capacity, the body’s ability to repair itself, that declines as we age.
Elevian’s founders have identified circulating blood factors, including GDF11, that broadly stimulate regenerative capacity in aged animals in many organs and tissues (e.g. brain, heart, pancreas, muscle, and others). Initially planned indications include Alzheimer’s disease, heart failure, Type II diabetes, and age-related muscle dysfunction.
Antoxerene uses proprietary next generation screening technology to identify small-molecule compounds that target pathways of aging.
The team focuses on next generation screens with higher predictive value than traditional approaches and expects first on-target therapeutic candidates for the p53/MDM2 pathway, a major oncology target, and the p53/FOXO4 pathway, a newly identified pathway involved in cellular aging.
FoxBio will develop Antoxerene’s collection of small molecules that specifically target senescent cells.
There has been a lot of interest surrounding the therapeutic applications of senolytic drugs – compounds that clear toxic senescent cells – particularly with respect to age-associated disease. As molecular pathways unique to senescent cells have begun to be identified, drugs to target these pathways can now be developed.
AgeX is applying technology relating to cell immortality and regenerative biology, to aging and age-related diseases.
The company has three initial areas of product development: pluripotent stem cell-derived brown adipocytes; vascular progenitors; and induced tissue regeneration. Initial planned indications for these products are Type II diabetes, cardiac ischemia, and cancer respectively.
When a cell reaches the end of its life or becomes damaged beyond repair, it is supposed to either kill itself or signal the immune system to remove it. Unfortunately, every so often this mechanism fails, the cell stays around indefinitely and starts poisoning its environment. Over time we accumulate more and more of these harmful, death-resistant senescent cells.
A recent study in rodents has shown that clearing senescent cells can both reduce the adverse effects of age-related diseases and extend the healthy lifespan by up to 35%.
Oisin is developing a cellular repair therapy based on a genetically-targeted intervention to clear senescent cells from our body.
Age-related macular degeneration (AMD) is the leading cause of vision loss among people over the age of 50.
AMD is thought to be caused by aggregation of A2E a toxic, non-degradable cellular waste product in our eye's retinal cells.
Lysoclear is a molecular repair therapy based on the targeted delivery of exogenous A2E degrading enzymes to our retina cells to eliminate A2E, treat AMD and restore vision.
The team recently announced a Series-A offering to bring its product through Phase I clinical trials. LysoClear would be the first clinical candidate based on the repair and rejuvenation paradigm, pioneered by the SENS research foundation.
CellAge is aiming to increase human healthspan and reduce the incidence of age-related diseases by helping the human body destroy senescent cells.
The team is focusing on a novel approach for this challenge by developing synthetic promoters for senescence cell detection and removal.
The joint expertise in senescence, synthetic biology and bioinformatics gives CellAge a unique angle on improving ways that gene therapies could be targeted to senescent cells.